Abstract
Interferon (IFN)-α therapy may induce, reveal, or exacerbate various autoimmunerelated disorders. We describe a 48-year-old female patient who developed muscle waakness during IFN-α therapy given for hepatitis C virus-associated chronic active hepatitis. This symptom diminished slightly after discontinuation of the therapy, but she then began to complain of Raynaud’s phenomenon, swelling of bilateral dorsal hands and dysphagia. Accompanied by an elevation of serum antinuclear antibody, the subsequent development of polymyositis (PM) and progressive systemic sclerosis was considered to have been induced by the IFN-α.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Davies GL, Balart LA, Schiff ERet al., Hepatitis Interventional Therapy Group. Treatment of hepatitis C with recombinant interferon alpha. A multicenter, randomized, controlled trial,N Engl J Med 321, 1501–1506 (1989).
Ronnblom LE, Alm GV, Oberg KE, Possible induction of systemic lupus erythematosus by interferon α treatment in a patient with a malignant carcinoid tumor,J Intern Med 227, 207–210 (1990).
Garcia-Porrua C, Gonzalez-Gay MA, Fernandez-Lamelo Fet al., Simultaneous development of SLE-like syndrome and autoimmune thyroiditis following α-interferon treatment,Clin Exp Rheumatol 16, 107–108 (1998).
Iguchi H, Kishi M, Fujioka Tet al., Polymyositis after interferon β treatment of chronic hepatitis type C,Clin Neurol 36, 22–24 (1996).
Arai H, Tanaka M, Ohta Ket al., Symptomatic myopathy associated with interferon therapy for chronic hepatitis C,Lancet 345, 582 (1995).
Prior C, Haslam PL,In vivo levels andin vitro production of interferon-gamma in fibrosing interstitial lung disease,Clin Exp Immunol 88, 280–287 (1992).
Stevens W, Vancheeswaran R, Black CM, Alpha interferon-2α (Roferon-A) in the treatment of diffuse cutaneous systemic sclerosis: a pilot study,Br J Rheumatol 31, 683–689 (1992).
Hooks JJ, Moutsopoulus HM, Geis SAet al., Immune interferon in the circulation of patients with autoimmune disease,N Engl J Med 301, 4–8 (1979).
Nagayama Y, Ohta K, Tsuruta Met al., Exacerbation of thyroid autoimmunity by interferon α treatment in patients with chronic viral hepatitis: our studies and review of the literature,Endocr J 41, 565 (1994).
Pittau E, Bogliolo A, Tinti Aet al., Development of arthritis and hypothyroidism during alpha-interferon therapy for chronic hepatitis C,Clin Exp Rheumatol 15, 415–419 (1997).
Taniguchi O, Miyajima H, Hirano T,et al., The Leu-1 B-cell subpopulation in patients with rheumatoid arthritis,J Clin Immunol 7, 441–448 (1987).
Vallisa D, Cavanna L, Berte Ret al., Autoimmune thyroid dysfunction in hematologic malignancies treated with alpha-interferon,Acta Haematol 93, 31–35 (1995).
Yamada G, Tsuji T, Immunological mechanism of chronic liver injury in viral hepatitis,Intern Med 32, 911–913 (1993).
Mishiro S, Hoshi Y, Takeda Ket al., Non-A, non-B hepatitis specific antibodies directed at host-derived epitope: implication for an autoimmune process,Lancet,336, 1400–1403 (1990).
Author information
Authors and Affiliations
About this article
Cite this article
Otsuka, T., Sakamoto, N., Tanaka, Y. et al. Overlap syndrome of polymyositis and progressive systemic sclerosis associated with interferon therapy for chronic hepatitis C. Japanese Journal of Rheumatology 9, 259–265 (1999). https://doi.org/10.1007/BF03041283
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF03041283